Triple combination cancer immunotherapy improves outcomes in preclinical melanoma model
Adoptive cell transfer (ACT) is a promising cancer immunotherapy that involves isolating T cells from cancer patients that are capable of targeting their tumor, selecting the more active T cells and expanding those in the lab, and then transfusing them back into patients. ACT is already available in the clinic for some diseases — CAR… Read More: Triple combination cancer immunotherapy improves outcomes in preclinical melanoma model »